Sponsors Will Need New Databases And Metrics To Determine Success Of Opioids REMS

FDA sees REMS assessment as a collaborative effort and already has initiatives with other federal agencies to find ways to monitor indicators of effectiveness.

More from Archive

More from Pink Sheet